Credit Suisse initiated coverage on Invitae with a new price target
$NVTA
Medical Specialities
Health Care
Credit Suisse initiated coverage of Invitae with a rating of Underperform and set a new price target of $1.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/5/2023 | Underweight | JP Morgan | |
| 5/15/2023 | Mkt Perform → Underperform | Raymond James | |
| 1/31/2023 | $2.00 | Neutral → Sell | Goldman |
| 8/25/2022 | $1.00 | Underperform | Credit Suisse |
| 8/10/2022 | Neutral → Underweight | JP Morgan | |
| 7/26/2022 | $8.00 → $2.50 | Outperform → Market Perform | Cowen |
| 7/21/2022 | Outperform → Mkt Perform | Raymond James | |
| 7/20/2022 | Buy → Neutral | Ladenburg Thalmann |
Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 BURLINGTON, N.C., April 24, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that it has been selected as the winning bidder for select assets of Invitae, a leading medical genetics company. Before the transaction can proceed, the court overseeing the process must issue an approval order following a hearing currently scheduled for May 6, 2024.
– Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantially All of the Company's Assets, Ensuring Business Continuity for Customers, Partners and Employees – SAN FRANCISCO, April 24, 2024 /PRNewswire/ -- Invitae (OTC:NVTA), a leading medical genetics company, announced that Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, has been selected as the winning bidder in the Company's auction in its sale process under Section 363 of the U.S. Bankruptcy Code. Labcorp will acquire substantially all of the Company's assets on a going concern basis
– Report details the company's commitment to improving healthcare through the power of genetic information and discloses Environmental, Social and Governance initiatives for fiscal year 2023 – SAN FRANCISCO, April 22, 2024 /PRNewswire/ -- Invitae (OTC:NVTA), a leading medical genetics company, today published its 2024 Environmental, Social and Governance (ESG) Report. This report provides a holistic view of the company's approach to ESG and its performance and progress through measurable data and metrics during the 2023 fiscal year. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring c
4 - Invitae Corp (0001501134) (Issuer)
4 - Invitae Corp (0001501134) (Issuer)
4 - Invitae Corp (0001501134) (Issuer)